Page 2006 - Hematology_ Basic Principles and Practice ( PDFDrive )

1780 Part XI Transfusion Medicine

plasma pool while increasing product purity. Techniques in molecular Horowitz B, Wiebe ME, Lippin A, et al: Inactivation of viruses in labile
biology and heterologous expression of mammalian proteins have blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)
allowed for the production of some proteins, most notably factor VIII phosphate detergent combinations. Transfusion 25:516, 1985.
and factor IX, without reliance on the limited plasma resource. These Hunault M, Bauer KA: Recombinant factor VIIa for the treatment of con-
plasma-derived and recombinant concentrates have supplanted the genital factor VII deficiency. Semin Thromb Hemost 26(4):401–405, 2000.
use of plasma or cryoprecipitate for the treatment of some congenital Journeycake JM, Quinn CT, Miller KL, et al: Catheter-related deep venous
and acquired deficiencies of soluble plasma factors and have decreased thrombosis in children with hemophilia. Blood 98(6):1727–1731, 2001.
or eliminated the attendant risks of allergic reactions, volume over- Lancellotti S, Basso M, De Cristofaro R: Congenital prothrombin deficiency:
load, and pathogen transmission. For patients on home infusion an update. Semin Thromb Hemost 39(6):596–606, 2013.
regimens, protein concentrates also have the benefit of increasing Leissinger C, Gringeri A, Antmen B, et al: Anti-inhibitor coagulant complex
patient convenience because infusion volumes are small relative to prophylaxis in hemophilia with inhibitors. N Engl J Med 365:18, 2011.
blood component therapy. Although the development of high-purity, Lusher JM, Arkin S, Abildgaard CF, et al: Recombinant factor VIII for the
virally safe concentrates to treat other plasma protein deficiencies that treatment of previously untreated patients with hemophilia A: safety,
are currently treated with blood components is technically feasible, efficacy, and development of inhibitors. Kogenate Previously Untreated
such development is limited by the very small numbers of patients Patient Study Group. N Engl J Med 328:453, 1993.
with these disorders. In the future, the development of products Mannucci PM: Haemophilia treatment protocols around the world: towards
produced in transgenic animals holds the promise of producing large a consensus. Haemophilia 4(4):421, 1998.
quantities of recombinant proteins, thus making available more of Mannucci PM, Carlsson S, Harris AS: Desmopressin, surgery and thrombo-
these lifesaving products for use clinically. Long-acting factor prod- sis. Thromb Haemost 71(1):154–155, 1994.
ucts have now been approved and may improve quality of life while Mariani G, Testa MG, Di Paolantonio T, et al: Use of recombinant, activated
reducing the number of weekly infusions and limiting the need for factor VII in the treatment of congenital factor VII deficiencies. Vox Sang
venous access devices. Novel delivery methods for factor VIII defi- 77(3):131–136, 1999.
ciency, such as weekly subcutaneous injections are being explored. Mumford AD, Ackroyd S, Alikhan R, et al: Guideline for the diagnosis
Profound progress has been made in terms of a curative treatment, and management of the rare coagulation disorders: a United Kingdom
gene therapy for factor IX deficiency. This is a most promising time Haemophilia Centre Doctors’ Organization guideline on behalf of
for the management of patients with hemophilia and rare inherited the British Committee for Standards in Haematology. Br J Haematol
factor deficiencies. 167(3):304–326, 2014.
Nathwani AC, Tuddenham EG, Rangarajan S, et al: Adenovirus-associated
virus vector-mediated gene transfer in hemophilia B. N Engl J Med
SUGGESTED READINGS 365(25):2357–2365, 2011.
Nathwani AC, Reiss UM, Tuddenham EG, et al: Long-term safety and
Bolton-Maggs PH, Perry DJ, Chalmers EA, et al: The rare coagulation efficacy of factor IX gene therapy in hemophilia B. N Engl J Med
disorders–review with guidelines for management from the United 371(21):1994–2004, 2014.
Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia Nilsson IM, Berntorp E, Zettervall O: Induction of immune tolerance in
10:593, 2004. patients with hemophilia and antibodies to factor VIII by combined
Brand-Staufer B, Carcao M, Kerlin BA, et al: Pharmacokinetic characteriza- treatment with intravenous IgG, cyclophosphamide, and factor VIII. N
tion of recombinant factor XIII (FXIII)-A2 across age groups in patients Engl J Med 318:947, 1988.
with FXIII A-subunit congenital deficiency. Haemophilia 21(3):380–385, Optimal treatment strategies for hemophilia: achievements and limitations
2015. of current prophylactic regimens. Oldenburg J Blood 125(13):2038–2044,
Bray GL, Gomperts ED, Courter S, et al: A multicenter study of recombinant 2015.
factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously Ragni MV, Fogarty PJ, Josephson NC, et al: Survey of current prophylaxis
untreated patients with hemophilia A. The Recombinate Study Group. practices and bleeding characteristics of children with severe haemophilia
Blood 83:2428, 1994. A in US haemophilia treatment centres. Haemophilia 2011.
Carcao M, St Louis J, Poon MC, et al: Rituximab for congenital haemo- Roberts H: The treatment of hemophilia: past tragedy and future promise.
philiacs with inhibitors: a Canadian experience. Haemophilia 12(1):7–18, N Engl J Med 321:1188, 1989.
2006. Schwartz RS, Abildgaard C, Aledort L, et al: Group TRFVS: human recom-
DiMichele DM: Inhibitors in haemophilia: a primer. Haemophilia 6(Suppl binant DNA derived antihemophilic (factor VIII) in the treatment of
1):38–40, 2000. hemophilia A. N Engl J Med 323:1800, 1990.
Ehrenforth S, Kreutz W, Scharrer I, et al: Incidence of development of United Kingdom Haemophilia Centre Doctor’s Organization: Guidelines on
factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594, the selection and use of therapeutic products to treat haemophilia and
1992. other hereditary bleeding disorders. Haemophilia 9:1, 2003.
Feldman BM, Pai M, Rivard GE, et al: Tailored prophylaxis in severe hemo- Valentino LA, Ewenstein B, Navickis RJ, et al: Central venous access devices
philia A: interim results from the first 5 years of the Canadian Hemophilia in haemophilia. Haemophilia 10(2):134–146, 2004.
Primary Prophylaxis Study. J Thromb Haemost 4(6):1228–1236, 2006. White GC, Beebe A, Nielsen B: Recombinant factor IX. Thromb Haemost
Franchini M, Mannucci PM: Inhibitor eradication with rituximab in haemo- 78:261, 1997.
philia: where do we stand? Br J Haematol 165(5):600–608, 2014.
Green D: Complications associated with the treatment of haemophiliacs with
inhibitors. Haemophilia 5(Suppl 3):11–17, 1999. REFERENCES
High KA, Factor IX: molecular structure, epitopes, and mutations associated
with inhibitor formation. Adv Exp Med Biol 386:79–86, 1995. For the complete list of references, log on to www.expertconsult.com.